1
|
Lorthioir A, Belmihoub I, Fouassier D, Azizi M, Amar L. [Spironolactone in resistant essential hypertension]. Presse Med 2019; 48:1431-1438. [PMID: 31473027 DOI: 10.1016/j.lpm.2019.07.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 07/23/2019] [Indexed: 11/26/2022] Open
Abstract
Resistant hypertension is defined as uncontrolled blood pressure (BP) despite three antihypertensive agents including a diuretic (thiazide diuretic if renal function is normal or loop diuretic in case of chronic kidney disease with eGFR<30mL/min), a renin-angiotensin system blocker (ARB or ACEI) and a calcium channel blocker, at optimal doses. Resistance must be confirmed by out-of-office measurements (ambulatory blood pressure monitoring or home blood pressure monitoring) and patients should be asked about treatment compliance and excessive salt or alcohol intake. If the diagnosis of resistant hypertension is confirmed, the patient should be referred to a hypertension specialist to screen for secondary causes of hypertension as they are frequent in this context. If essential resistant hypertension is confirmed, the mineralocorticoid receptor antagonist, spironolactone, should be added (25 to 50mg daily). In the event of a contraindication to spironolactone, or if adverse effects occur, a beta-blocker, an alpha-blocker, or a centrally acting antihypertensive drug should be prescribed.
Collapse
Affiliation(s)
- Aurélien Lorthioir
- AP-HP, hôpital européen Georges-Pompidou, hypertension unit, 20, rue Leblanc, 75015 Paris, France.
| | - Inès Belmihoub
- AP-HP, hôpital européen Georges-Pompidou, hypertension unit, 20, rue Leblanc, 75015 Paris, France; Paris-Descartes university, faculty of medicine, 75006 Paris, France
| | - David Fouassier
- Paris-Descartes university, faculty of medicine, 75006 Paris, France; AP-HP, hôpital Européen Georges Pompidou, Centre d'Investigation Clinique, 20, rue Leblanc, 75015 Paris, France
| | - Michel Azizi
- AP-HP, hôpital européen Georges-Pompidou, hypertension unit, 20, rue Leblanc, 75015 Paris, France; Paris-Descartes university, faculty of medicine, 75006 Paris, France; AP-HP, hôpital Européen Georges Pompidou, Centre d'Investigation Clinique, 20, rue Leblanc, 75015 Paris, France
| | - Laurence Amar
- AP-HP, hôpital européen Georges-Pompidou, hypertension unit, 20, rue Leblanc, 75015 Paris, France; Paris-Descartes university, faculty of medicine, 75006 Paris, France
| |
Collapse
|